S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
BREAKING: Tiny biotech successfully treats blindness (Ad)
How major US stock indexes fared Friday, 9/29/2023
MarketBeat Week in Review – 9/25 - 9/29
BREAKING: Tiny biotech successfully treats blindness (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Closing prices for crude oil, gold and other commodities
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
BREAKING: Tiny biotech successfully treats blindness (Ad)
How major US stock indexes fared Friday, 9/29/2023
MarketBeat Week in Review – 9/25 - 9/29
BREAKING: Tiny biotech successfully treats blindness (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Closing prices for crude oil, gold and other commodities
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
BREAKING: Tiny biotech successfully treats blindness (Ad)
How major US stock indexes fared Friday, 9/29/2023
MarketBeat Week in Review – 9/25 - 9/29
BREAKING: Tiny biotech successfully treats blindness (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Closing prices for crude oil, gold and other commodities
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
BREAKING: Tiny biotech successfully treats blindness (Ad)
How major US stock indexes fared Friday, 9/29/2023
MarketBeat Week in Review – 9/25 - 9/29
BREAKING: Tiny biotech successfully treats blindness (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Closing prices for crude oil, gold and other commodities
NASDAQ:LYEL

Lyell Immunopharma (LYEL) Stock Forecast, Price & News

$1.47
-0.10 (-6.37%)
(As of 09/29/2023 ET)
Compare
Today's Range
$1.44
$1.63
50-Day Range
$1.45
$3.10
52-Week Range
$1.39
$8.25
Volume
940,419 shs
Average Volume
778,199 shs
Market Capitalization
$369.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.25

Lyell Immunopharma MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
325.2% Upside
$6.25 Price Target
Short Interest
Bearish
17.22% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.98mentions of Lyell Immunopharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.08) to ($1.19) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.05 out of 5 stars

Medical Sector

571st out of 970 stocks

Pharmaceutical Preparations Industry

271st out of 450 stocks


LYEL stock logo

About Lyell Immunopharma (NASDAQ:LYEL) Stock

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, engages in developing T-cell reprogramming technologies for patients with solid tumors. It develops therapies using an ex vivo genetic reprogramming technologies, such as c-Jun overexpression and NR4A3 gene knockout, to endow resistance to T-cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi-R to generate population of T cells with durable stemness, and Stim-R, a proprietary synthetic cell mimetic. The company's pipeline includes LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T-cell product candidate for the treatment of various solid tumors; LYL845, an epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate that targets multiple solid tumors; LYL119, a CAR T-cell product candidate for enhanced cytotoxicity. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

LYEL Price History

LYEL Stock News Headlines

Lyell Immunopharma Shares Up 8% on Cellares Collaboration
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Why Shares of Lyell Immunopharma Jumped This Week
Lyell Immunopharma (LYEL) Receives a Buy from H.C. Wainwright
See More Headlines
Receive LYEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lyell Immunopharma and its competitors with MarketBeat's FREE daily newsletter.

LYEL Company Calendar

Last Earnings
8/08/2023
Today
9/30/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LYEL
Fax
N/A
Employees
274
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.25
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+325.2%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Net Income
$-183,120,000.00
Net Margins
-432.13%
Pretax Margin
-432.13%

Debt

Sales & Book Value

Annual Sales
$84.68 million
Book Value
$3.34 per share

Miscellaneous

Free Float
190,781,000
Market Cap
$369.01 million
Optionable
Not Optionable
Beta
-1.38
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Richard D. Klausner M.D. (Age 71)
    Founder & Exec. Chairman
    Comp: $80k
  • Dr. Lynn Seely M.D. (Age 64)
    Ph.D., Pres, CEO & Director
    Comp: $430.69k
  • Mr. Charles W. Newton (Age 52)
    Chief Financial Officer
    Comp: $1.72M
  • Mr. Stephen J. Hill (Age 53)
    Chief Operating Officer
    Comp: $1.04M
  • Dr. Gary Lee Ph.D. (Age 46)
    Chief Scientific Officer
    Comp: $639.91k
  • Ms. Elizabeth Homans (Age 57)
    Consultant
    Comp: $1.99M
  • Prof. Stanley R. Riddell M.D.
    Founder & Scientific Advisor
  • Dr. Crystal L. Mackall M.D.
    Founder & Scientific Advisor
  • Nellie Dillery
    Director of Accounting
  • Ms. Ellen Rose
    Sr. VP of Communications & Investor Relations













LYEL Stock - Frequently Asked Questions

Should I buy or sell Lyell Immunopharma stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lyell Immunopharma in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" LYEL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LYEL, but not buy additional shares or sell existing shares.
View LYEL analyst ratings
or view top-rated stocks.

What is Lyell Immunopharma's stock price forecast for 2023?

4 Wall Street research analysts have issued 1 year price objectives for Lyell Immunopharma's shares. Their LYEL share price forecasts range from $4.00 to $9.00. On average, they predict the company's stock price to reach $6.25 in the next twelve months. This suggests a possible upside of 325.2% from the stock's current price.
View analysts price targets for LYEL
or view top-rated stocks among Wall Street analysts.

How have LYEL shares performed in 2023?

Lyell Immunopharma's stock was trading at $3.47 at the beginning of 2023. Since then, LYEL shares have decreased by 57.6% and is now trading at $1.47.
View the best growth stocks for 2023 here
.

When is Lyell Immunopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our LYEL earnings forecast
.

How were Lyell Immunopharma's earnings last quarter?

Lyell Immunopharma, Inc. (NASDAQ:LYEL) released its earnings results on Tuesday, August, 8th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.04. The company had revenue of $0.03 million for the quarter, compared to analysts' expectations of $3.31 million. Lyell Immunopharma had a negative trailing twelve-month return on equity of 26.40% and a negative net margin of 432.13%.

When did Lyell Immunopharma IPO?

(LYEL) raised $425 million in an initial public offering (IPO) on Thursday, June 17th 2021. The company issued 25,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, BofA Securities, J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO.

What is Lyell Immunopharma's stock symbol?

Lyell Immunopharma trades on the NASDAQ under the ticker symbol "LYEL."

How do I buy shares of Lyell Immunopharma?

Shares of LYEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lyell Immunopharma's stock price today?

One share of LYEL stock can currently be purchased for approximately $1.47.

How much money does Lyell Immunopharma make?

Lyell Immunopharma (NASDAQ:LYEL) has a market capitalization of $369.01 million and generates $84.68 million in revenue each year. The company earns $-183,120,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis.

How many employees does Lyell Immunopharma have?

The company employs 274 workers across the globe.

How can I contact Lyell Immunopharma?

The official website for the company is www.lyell.com. The company can be reached via phone at 650-695-0677 or via email at erose@lyell.com.

This page (NASDAQ:LYEL) was last updated on 9/30/2023 by MarketBeat.com Staff

My Account -